Related references
Note: Only part of the references are listed.Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: Results of a phase IIb dose-ranging study
Christie M. Ballantyne et al.
AMERICAN HEART JOURNAL (2012)
Solubility and stability of dalcetrapib in vehicles and biological media
Guenter Gross et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2012)
Evidence of a Drug-Drug Interaction Linked to Inhibition of Ester Hydrolysis by Orlistat
Darren Bentley et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2012)
Determination of dalcetrapib by liquid chromatography-tandem mass spectrometry
Katja Heinig et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2012)
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lipid Disorders and Their Relevance to Outcomes in Chronic Kidney Disease
Nosratola D. Vaziri et al.
BLOOD PURIFICATION (2011)
Evolving Concepts of the Role of High-Density Lipoprotein in Protection from Atherosclerosis
John A. Farmer et al.
CURRENT ATHEROSCLEROSIS REPORTS (2011)
HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms
Mohamad Navab et al.
NATURE REVIEWS CARDIOLOGY (2011)
Dalcetrapib pharmacokinetics and metabolism in the cynomolgus monkey
Olaf Kuhlmann et al.
XENOBIOTICA (2011)
Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial
Evan A. Stein et al.
EUROPEAN HEART JOURNAL (2010)
Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing
Michael Derks et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma
Amelia J. Hessheimer et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2010)
No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin
Michael Derks et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Biochemical characterization of cholesteryl ester transfer protein inhibitors
Mollie Ranalletta et al.
JOURNAL OF LIPID RESEARCH (2010)
Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport
Eric J. Niesor et al.
JOURNAL OF LIPID RESEARCH (2010)
On the Influence of Protein Binding on Pharmacological Activity of Drugs
Leonid M. Berezhkovskiy
JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis
Kunihiro Matsushita et al.
LANCET (2010)
HDL metabolism and activity in chronic kidney disease
Nosratola D. Vaziri et al.
NATURE REVIEWS NEPHROLOGY (2010)
Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome
Gregory G. Schwartz et al.
AMERICAN HEART JOURNAL (2009)
Safety and Tolerability of Dalcetrapib
Evan A. Stein et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Assessment of the Impact of Renal Impairment on Systemic Exposure of New Molecular Entities: Evaluation of Recent New Drug Applications
Y. Zhang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
The Influence of Chronic Renal Failure on Drug Metabolism and Transport
A. W. Dreisbach
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
A Single-Center, Open-Label, One-Sequence Study of Dalcetrapib Coadministered With Ketoconazole, and an In Vitro Study of the S-Methyl Metabolite of Dalcetrapib
Michael Derks et al.
CLINICAL THERAPEUTICS (2009)
Lipid and Lipoprotein Metabolism in Chronic Kidney Disease
Geoige A. Kaysen
JOURNAL OF RENAL NUTRITION (2009)
Causes of Dysregulation of Lipid Metabolism in Chronic Renal Failure
Nosratola D. Vaziri
SEMINARS IN DIALYSIS (2009)
Chronic kidney disease as a predictor of cardiovascular disease (from the Framingham Heart Study)
Nisha I. Parikh et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia
Jean-Charles Fruchart et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction
Roger K. Verbeeck
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
The effect of chronic renal failure on drug metabolism and transport
Albert W. Dreisbach et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2008)
The hepatic sinusoid in aging and cirrhosis - Effects on hepatic substrate disposition and drug clearance
DG Le Couteur et al.
CLINICAL PHARMACOKINETICS (2005)
Dose adjustment in patients with liver disease
F Delco et al.
DRUG SAFETY (2005)
Protein thiol oxidation and lipid peroxidation in patients with uraemia
M Prakash et al.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2004)
A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
H Okamoto et al.
NATURE (2000)
Share Paper
